These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2116 related articles for article (PubMed ID: 28052254)

  • 41. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.
    Van Nuffel AM; Tuyaerts S; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A
    J Immunol Methods; 2012 Mar; 377(1-2):23-36. PubMed ID: 22269772
    [TBL] [Abstract][Full Text] [Related]  

  • 42. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
    Voron T; Colussi O; Marcheteau E; Pernot S; Nizard M; Pointet AL; Latreche S; Bergaya S; Benhamouda N; Tanchot C; Stockmann C; Combe P; Berger A; Zinzindohoue F; Yagita H; Tartour E; Taieb J; Terme M
    J Exp Med; 2015 Feb; 212(2):139-48. PubMed ID: 25601652
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
    Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
    Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.
    Davoli T; Uno H; Wooten EC; Elledge SJ
    Science; 2017 Jan; 355(6322):. PubMed ID: 28104840
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
    Adachi K; Tamada K
    Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genomic Approaches to Understanding Response and Resistance to Immunotherapy.
    Braun DA; Burke KP; Van Allen EM
    Clin Cancer Res; 2016 Dec; 22(23):5642-5650. PubMed ID: 27698000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories.
    Mizuno S; Yamaguchi R; Hasegawa T; Hayashi S; Fujita M; Zhang F; Koh Y; Lee SY; Yoon SS; Shimizu E; Komura M; Fujimoto A; Nagai M; Kato M; Liang H; Miyano S; Zhang Z; Nakagawa H; Imoto S
    Sci Rep; 2021 Aug; 11(1):15713. PubMed ID: 34344966
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy.
    Li X; Song W; Shao C; Shi Y; Han W
    Cell Mol Immunol; 2019 Jan; 16(1):28-39. PubMed ID: 30002451
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response.
    Mardis ER
    Genome Med; 2019 Nov; 11(1):71. PubMed ID: 31747945
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genomic determinants of cancer immunotherapy.
    Miao D; Van Allen EM
    Curr Opin Immunol; 2016 Aug; 41():32-38. PubMed ID: 27254251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapy: personalizing tumour vaccines.
    Killock D
    Nat Rev Clin Oncol; 2015 Feb; 12(2):64. PubMed ID: 25511189
    [No Abstract]   [Full Text] [Related]  

  • 53. B7S1, a novel candidate for anti-tumor checkpoint blockade immunotherapy.
    Chen X; Ye L
    Sci China Life Sci; 2018 Sep; 61(9):1132-1134. PubMed ID: 30069671
    [No Abstract]   [Full Text] [Related]  

  • 54. Gene-expression profiling to predict responsiveness to immunotherapy.
    Jamieson NB; Maker AV
    Cancer Gene Ther; 2017 Mar; 24(3):134-140. PubMed ID: 27834354
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.
    Ock CY; Hwang JE; Keam B; Kim SB; Shim JJ; Jang HJ; Park S; Sohn BH; Cha M; Ajani JA; Kopetz S; Lee KW; Kim TM; Heo DS; Lee JS
    Nat Commun; 2017 Oct; 8(1):1050. PubMed ID: 29051489
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pan-cancer immunogenomic analyses reveal sex disparity in the efficacy of cancer immunotherapy.
    Wang PF; Song HF; Zhang Q; Yan CX
    Eur J Cancer; 2020 Feb; 126():136-138. PubMed ID: 31927214
    [No Abstract]   [Full Text] [Related]  

  • 57. Discovery of putative breast cancer antigens using an integrative platform of genomics-driven immunoproteomics.
    Qendro V; Lundgren DH; Palczewski S; Hegde P; Stevenson C; Perpetua L; Latifi A; Merriman J; Bugos G; Han DK
    Proteomics; 2017 Aug; 17(15-16):. PubMed ID: 28665052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response to Immune Checkpoint Blockade is Influenced by
    Cancer Discov; 2018 Feb; 8(2):139. PubMed ID: 29247014
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Basic Overview of Current Immunotherapy Approaches in Cancer.
    Velcheti V; Schalper K
    Am Soc Clin Oncol Educ Book; 2016; 35():298-308. PubMed ID: 27249709
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TIP: A Web Server for Resolving Tumor Immunophenotype Profiling.
    Xu L; Deng C; Pang B; Zhang X; Liu W; Liao G; Yuan H; Cheng P; Li F; Long Z; Yan M; Zhao T; Xiao Y; Li X
    Cancer Res; 2018 Dec; 78(23):6575-6580. PubMed ID: 30154154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 106.